New drug combo aims to stop breast cancer return in High-Risk patients
NCT ID NCT05760612
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a combination of trastuzumab and neratinib works better than the standard trastuzumab and pertuzumab for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) who still have small amounts of cancer after initial chemotherapy and targeted therapy. About 300 women will be randomly assigned to one of the two drug pairs. The main goal is to see which combination better prevents the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab and neratinib (drug combination)
What this could lead to
If successful, this could offer a more effective treatment option for HER2-positive breast cancer patients who still have some cancer after initial therapy, potentially reducing the risk of the cancer coming back.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The new combination may not be better than the current standard, and side effects like diarrhea or heart problems are possible. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••